120 related articles for article (PubMed ID: 36637236)
1. Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat.
Nouibi C; Cherif Chefchaouni A; Bechar H; Belahcen MJ; Rahali Y
J Oncol Pharm Pract; 2023 Oct; 29(7):1708-1714. PubMed ID: 36637236
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
[TBL] [Abstract][Full Text] [Related]
4. Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
Jiang Y; Mason M; Cho Y; Chittiprolu A; Zhang X; Harden K; Gong Y; Harris MR; Barton DL
BMC Cancer; 2022 Sep; 22(1):950. PubMed ID: 36057578
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the practice of prescribing oral chemotherapy type "Capecitabine" by medical oncologist: A first study from Morocco].
Kharmoum S; Najdi A; Rahhali R; Meliani M; Boutayeb S; Mrabti H; El Ghissassi I; Afqir S; Mellas N; Ichou M; El M'Rabet FZ; Errihani H
Bull Cancer; 2021 Oct; 108(10):940-947. PubMed ID: 34281729
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
10. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Pilancı KN; Saglam S; Okyar A; Yucel S; Pala-Kara Z; Ordu C; Namal E; Ciftci R; Iner-Koksal U; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):143-50. PubMed ID: 27270460
[TBL] [Abstract][Full Text] [Related]
11. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
Iimura Y; Furukawa N; Ishibashi M; Ahiko Y; Tanabe T; Aikou S; Shida D; Nojima M; Kuroda S; Boku N
BMC Gastroenterol; 2022 Jul; 22(1):341. PubMed ID: 35836104
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
13. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
14. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH
Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686
[TBL] [Abstract][Full Text] [Related]
15. MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.
Camera S; Deleporte A; Bregni G; Trevisi E; Pretta A; Telli TA; Polastro L; Gombos A; Kayumba A; Ameye L; Piccart-Gebhart M; Awada A; Sclafani F; Hendlisz A
Clin Colorectal Cancer; 2020 Dec; 19(4):311-318.e1. PubMed ID: 32631787
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer.
Cassata A; Procoplo G; Alù M; Ferrari L; Ferrario E; Beretta E; Longarini R; Busto G; De Candis D; Bajetta E
Tumori; 2001; 87(6):364-71. PubMed ID: 11989587
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
Daher Abdi Z; Lavau-Denes S; Prémaud A; Urien S; Sauvage FL; Martin J; Leobon S; Marquet P; Tubiana-Mathieu N; Rousseau A
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1285-93. PubMed ID: 24801171
[TBL] [Abstract][Full Text] [Related]
18. Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Le Saux O; Bourmaud A; Rioufol C; Colomban O; Guitton J; Schwiertz V; Regnier V; You B; Ranchon F; Maraval-Gaget R; Girard P; Chauvin F; Freyer G; Tod M; Henin E; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):319-327. PubMed ID: 29948022
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
20. Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Kibudde S; Begg W
Pan Afr Med J; 2022; 42():141. PubMed ID: 36160274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
